suplatast

出典: meddic

スプラタスト

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/16 09:06:37」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.
  • Hashizume H, Umayahara T.
  • European journal of dermatology : EJD.Eur J Dermatol.2014 Apr 11. [Epub ahead of print]
  • PMID 24723649
  • Prophylactic Effectiveness of Suplatast Tosilate in Children with Asthma Symptoms in the Autumn: A Pilot Study.
  • Yoshihara S1, Yamada Y2, Fukuda H1, Tsuchiya T2, Ono M3, Fukuda N4, Kanno N5, Arisaka O1.Author information 1Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.2Tsuchiya Children's Hospital, Saitama, Japan.3Nogi Hospital, Tochigi, Japan.4Grimm Pediatric and Allergy Clinic, Tochigi, Japan.5Nishikata Hospital, Tochigi, Japan.AbstractBackground: Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however, the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previously, except for leukotriene receptor antagonists and Omalizmab. Methods: This study compared the prophylactic effectiveness of suplatast tosilate with that of mequitazine in children with asthma symptoms, which is usually exacerbated in the autumn. The study group comprised 27 children aged 2 to 15 years who required treatment for asthmatic attacks during the past year and tested positive at least for mite allergen in the preceding autumn. The subjects were randomly assigned to receive either suplatast or mequitazine. The primary endpoint of this study was the number of days without symptoms during the 8 weeks of treatment. In addition, the Japanese Pediatric Asthma Control Program (JPAC) scores were also recorded every 2 weeks in each group. Results: Overall, 14 patients received suplatast, and 13 received mequitazine for 8 weeks from September through early October. During follow-up, the number of days without symptoms and the total JPAC scores did not differ significantly between the groups. However, as compared with weeks 1 to 2 of treatment, the mean number of days without symptoms during weeks 7 to 8 increased significantly in only the suplatast group (8.6 vs. 11.5 days; p = 0.004). Conclusions: Our results suggest that short-term additional treatment with suplatast is useful for preventing asthma symptoms in children with asthma, which is usually exacerbated in the autumn.
  • Allergology international : official journal of the Japanese Society of Allergology.Allergol Int.2014 Feb 25. [Epub ahead of print]
  • Background: Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however, the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previously, except for leukotriene receptor antagonists and Omalizmab. Methods: This study compar
  • PMID 24561769
  • Four new polymorphic forms of suplatast tosilate.
  • Nagai K1, Ushio T2, Miura H3, Nakamura T4, Moribe K5, Yamamoto K5.Author information 1Taiho Pharmaceutical Co. Ltd., Ebisuno, Hiraishi, Kawauchi-cho, Tokushima 771-0194, Japan; Graduate School of Pharmaceutical Sciences, Chiba University, Inohana, Chuo-ku, Chiba 260-8675, Japan. Electronic address: kei-nagai@taiho.co.jp.2Ace Japan Co. Ltd., Higashine-koh, Higashine, Yamagata 999-3701, Japan.3Taiho Pharmaceutical Co. Ltd., Kamikawa-machi, Kodama-gun, Saitama 367-0241, Japan.4RIKEN, Wako, Saitama 351-0198, Japan.5Graduate School of Pharmaceutical Sciences, Chiba University, Inohana, Chuo-ku, Chiba 260-8675, Japan.AbstractWe found four new polymorphic forms (γ-, ε-, ζ-, and η-forms) of suplatast tosilate (ST) by recrystallization and seeding with ST-analogous compounds; three polymorphic forms (α-, β-, and δ-forms) of ST have been previously reported. The physicochemical properties of these new forms were investigated using infrared (IR) spectroscopy, solid-state nuclear magnetic resonance (NMR) spectroscopy, differential scanning calorimetry, and powder X-ray diffractometry. The presence of hydrogen bonds in the new forms was assessed from the IR and solid-state NMR spectra. The crystal structures of the ε- and η-forms were determined from their powder X-ray diffraction data using the direct space approach and the Monte Carlo method, followed by Rietveld refinement. The structures determined for the ε- and η-forms supported the presence of hydrogen bonds between the ST molecules, as the IR and solid-state NMR spectra indicated. The thermodynamic characteristics of the seven polymorphic forms were evaluated by determining the solubility of each form. The α-form was the most insoluble in 2-propanol at 35°C, and was thus concluded to be the most stable form. The ε-form was the most soluble, and a polymorphic transition from the ε- to the α-form was observed during solubility testing.
  • International journal of pharmaceutics.Int J Pharm.2014 Jan 2;460(1-2):83-91. doi: 10.1016/j.ijpharm.2013.10.049. Epub 2013 Nov 6.
  • We found four new polymorphic forms (γ-, ε-, ζ-, and η-forms) of suplatast tosilate (ST) by recrystallization and seeding with ST-analogous compounds; three polymorphic forms (α-, β-, and δ-forms) of ST have been previously reported. The physicochemical properties of these new forms were inve
  • PMID 24211359

和文文献

  • 症例 トシル酸スプラタストとインドメタシンファルネシル内服併用を試みた木村病の1例
  • 阿部 真也,牛上 敢,西部 明子 [他]
  • 皮膚科の臨床 57(4), 439-443, 2015-04
  • NAID 40020439794
  • トシル酸スプラタスト(IPD)内服が有効であった好酸球性膀胱炎の1例
  • 倉本 朋未,線崎 博哉,稲垣 武
  • 泌尿器科紀要 = Acta urologica Japonica 60(9), 447-450, 2014-09
  • NAID 40020204087
  • トシル酸スプラタスト(IPD)内服が有効であった好酸球性膀胱炎の1例
  • 倉本 朋未,線崎 博哉,稲垣 武
  • 泌尿器科紀要 = Acta urologica Japonica 60(9), 447-450, 2014-09
  • … Therefore, she was treated with a combination of corticosteroid and suplatast tolilate, followed by monotherapy with suplatast tolilate. … The relief of the symptoms by suplatast tolilate therapy continued for five months. … Therefore, she was treated with a combination of suplatast tosilate, anti-allergic drugs and mirabegron. … Fourteen months after treatment with suplatast tosilate, no disease progression was noted. …
  • NAID 120005477656

関連リンク

スプラタストトシル酸塩(Suplatast tosilate)の検索ならお薬検索QLife(キューライフ)。お医者さんが処方する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、保管方法等を掲載。商品名だけでなく一般名や剤形、色 ...
スプラタストトシル酸塩(Suplatast tosilate)の検索ならお薬検索QLife(キューライフ)。お医者さんが処方する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、保管方法等を掲載。商品名だけでなく一般名や剤形、色 ...

関連画像

Cystitis Treated with Suplatast Topical suplatast tosilate (IPD File:Suplatast.png - Wikimedia CommonsSuplatast tosilate - Wikipedia, the free Figure 4 : New drugs for asthma : Nature between the benefits of suplatast


★リンクテーブル★
リンク元スプラタスト
拡張検索suplatast tosilate

スプラタスト」

  [★]

suplatast
トシル酸スプラタスト suplatast tosilate スプラタストトシル酸塩
アイピーディトシラート
  • T細胞のIL-4,IL-5産生抑制
  • ヒスタミン受容体拮抗作用無し→予防薬

作用機序

  • Th2細胞に作用しIL-4,IL-5分泌を抑制
  • IL-4, IL-5いずれもT細胞や肥満細胞から分泌される
IL-4は、B細胞活性化、IgEスイッチ
IL-5は、好酸球成長・分化
  • Th2細胞によるこれらのインターロイキン酸性を抑制することでIgE抗体産生抑制と好酸球の活性化が抑制される。

薬理作用

  • IgE抗体産生抑制
  • 好酸球浸潤抑制
  • 化学伝達物質遊離抑制



suplatast tosilate」

  [★]

suplatast




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡
週間・日々の人気記事
最近7日間の人気記事
 タイトル表示
1CATTLE BLEEDING LINE mail25
2CATTLE SKIN DEHIDER mail14
3SHEEP BLEEDING PULLEY mail11
4SHEEP BLEEDING LINE mail10
5CATTLE BLEEDING PAN mail9
6MONOSODIUM GLUTAMAT mail9
7SHEEP BLEEDING PAN mail9
8+spian calcium fluoride manufactures Co. ltd mail6
9chilaicliti+s症候群4
10+Angola mesh white herbal body talcum powder manufactures Co. ltd mail4
11右室梗塞4
12クモ膜嚢胞4
13右PICA後閉塞 s/o4
14裂脳症close4
15虫垂いんかんさいぼうがん4
16ソーセージ様手指とは4
17CATTLE BLEEDING HOOK mail3
18user/password3
19海綿+飼育3
20Squilla mantis a species of mantis shrimp mail3

昨日の人気記事
 タイトル表示
1MONOSODIUM GLUTAMAT mail4
2補正カルシウム+意味2
3人の交接器2
422. AL BAHR AL ARABI MARINE ENGINEERING SERVICES UAE mail2
5マイトジェン2
6膜内骨化+軟骨内骨化+違い2
7Youngmi mail2
8プトロピウム2
9有痛性けいれん2
10高リン血症 アシドーシス1
11血行動態性肺水腫1
12チフス 好酸球1
13頸椎骨軟骨症1
14呼吸筋疲労1
15永山斑1
16乳頭上膜とは+眼1
17乳頭上膜とは1
18迷走神経+徐脈1
19筋ジストロフィー+仮性肥大1
20高Na血症 低張尿1